7m
HealthDay on MSNShort-Course Vaginal Cuff Brachytherapy Feasible for Early-Stage Endometrial CancerShort-course vaginal cuff brachytherapy (VCB) is noninferior to standard regimens for short-term quality of life in people ...
Uterine cancer (also known as endometrial cancer) is the fourth most common cancer women in the U.S. are diagnosed with. It ...
In a randomized clinical trial, researchers from Huntsman Cancer Institute at the University of Utah (the U) have found that ...
Researchers at Huntsman Cancer Institute have found that fewer sessions of higher dose vaginal cuff brachytherapy work just ...
The American Cancer Society (ACS) has released Cancer Statistics for African American and Black People, 2025. According to ...
Endometrial cancer starts in the tissue that lines your uterus. If the cancer is platinum-resistant, platinum-based chemotherapy drugs will not work well to kill it or stop it from returning after ...
Black individuals had a 2-fold risk of cancer death related to prostate, myeloma, and stomach cancers compared with White ...
Drs Ursula A. Matulonis and Eloise Chapman-Davis discuss overcoming health disparities in endometrial cancer and increasing clinical trial enrollment of Black women.
8d
News Medical on MSNShort-course, higher dose vaginal brachytherapy for endometrial cancer shown to be effectiveIn a randomized clinical trial, researchers from Huntsman Cancer Institute at the University of Utah (the U) have found that short-course, higher dose vaginal brachytherapy for endometrial cancer had ...
The label for Jemperli plus chemotherapy in the U.S. was expanded to all adult patients with primary advanced or recurrent endometrial cancer in August 2024. Recently, GSK agreed to acquire IDRx ...
Medical experts emphasize the significance of early cancer detection. Learn about seven crucial warning signs that could ...
14d
GlobalData on MSNFDA grants breakthrough designation for Acrivon’s endometrial cancer assayThe US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 OncoSignature assay designed to detect endometrial cancer patients who can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results